The landscape of early drug development has changed radically over the last decade. The norms of the past, wherein first-in-human (FIH) studies consisted of a relatively straightforward series of observations following administration of small molecules to normal healthy volunteers, have given way to exponential increases in complexity.

Get access to a rapidly growing database of people who have given permission to be contacted directly for participation in clinical studies. Over 16,000 gastroenterology patients included in our global database deepening our insights to make your studies more efficient.

Over 16,000 autoimmune patients included in our global database deepening our insights to make your studies more efficient. Our surveys collect information on a wide variety of variables for each patient. Compare different populations of autoimmune patients.

Not all data is created equal. Leveraging our proprietary data enables us to deliver strong, viable protocol designs, faster patient recruitment and fewer non-performing sites than the industry average.

Eighteen biosimilars were approved by the FDA through the 351(k) pathway as of the end of March 2019, but the regulatory pathway in the U.S. is still considered a new frontier, especially when compared to regulatory guidance in the EU.

It can be a challenge to stay on top of the ever-changing regulatory landscape when looking to re-register or take a new chemical to market.

As crop protection products play such a crucial role in maintaining global crop yields to feed an ever-growing population, it's important that you are able to drive your product R&D forward with speed and accuracy - while staying on top of the always-shifting regulatory landscape.

After receiving Fast Track designation from the U.S.

This case study delves into how a sponsor and Labcorp Drug Development worked together to support a multi-faceted project for both biomarker discovery and assay development.